Pfizer is facing another setback with its weight-loss pill, danuglipron. The pharmaceutical giant stopped development of the drug after liver issues affected one patient.

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

"We request SEC and DoL take decisive action to uphold fiduciary duty laws," 22 state financial officers demanded in a letter to acting heads of both agencies.

Investors are plowing money into the two largest ETFs that track the S&P 500, the broadest measure of the U.S. stock market. But each has different bragging rights.

Americans are reaching retirement age at the fastest pace in U.S. history, and ETFs make it easier for investors to optimize their portfolios and gain exposure to specific sectors.

Journalist Matt Taibbi sounds off on the media and the White House "trying to tell people" that their perceptions of inflation and the economy are "irrational" or "partisan."

Telehealth company Ro has rolled out a new tool to track the supply of weight loss drugs like Ozempic and Wegovy across the U.S., as patients struggle with shortages.

While Warren Buffett is the largest investor in several of America's biggest companies, he also allocates some money into two ETFs that track the S&P 500, the broadest measure of U.S. stocks.

Nestlé's new food line, Vital Pursuit, is specifically targeted toward patients using weight-loss medications, which continues to surge in popularity.

Vanguard, the firm founded by John C. Bogle, may soon appoint the first outsider to be CEO in its 50-year history.